These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 25324181)

  • 1. Predictors of delay in diagnosis and treatment in diffuse large B-cell lymphoma and impact on survival.
    Nikonova A; Guirguis HR; Buckstein R; Cheung MC
    Br J Haematol; 2015 Feb; 168(4):492-500. PubMed ID: 25324181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival of patients with transformed lymphoma in the rituximab era.
    Guirguis HR; Cheung MC; Piliotis E; Spaner D; Berinstein NL; Imrie K; Zhang L; Buckstein R
    Ann Hematol; 2014 Jun; 93(6):1007-14. PubMed ID: 24414374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A retrospective analysis of primary gastric diffuse large B-cell lymphoma with or without concomitant mucosa-associated lymphoid tissue (MALT) lymphoma components.
    Li X; Xia B; Guo S; Zhan Z; Zhang L; Zhao D; Wu X; Zhang Y
    Ann Hematol; 2013 Jun; 92(6):807-15. PubMed ID: 23417758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns of failure in advanced stage diffuse large B-cell lymphoma patients after complete response to R-CHOP immunochemotherapy and the emerging role of consolidative radiation therapy.
    Shi Z; Das S; Okwan-Duodu D; Esiashvili N; Flowers C; Chen Z; Wang X; Jiang K; Nastoupil LJ; Khan MK
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):569-77. PubMed ID: 23540349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group.
    Pfreundschuh M; Kuhnt E; Trümper L; Osterborg A; Trneny M; Shepherd L; Gill DS; Walewski J; Pettengell R; Jaeger U; Zinzani PL; Shpilberg O; Kvaloy S; de Nully Brown P; Stahel R; Milpied N; López-Guillermo A; Poeschel V; Grass S; Loeffler M; Murawski N;
    Lancet Oncol; 2011 Oct; 12(11):1013-22. PubMed ID: 21940214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum albumin retains independent prognostic significance in diffuse large B-cell lymphoma in the post-rituximab era.
    Dalia S; Chavez J; Little B; Bello C; Fisher K; Lee JH; Chervenick P; Sokol L; Sotomayor E; Shah B
    Ann Hematol; 2014 Aug; 93(8):1305-12. PubMed ID: 24590536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma.
    Stefancikova L; Moulis M; Fabian P; Vasova I; Zedek F; Ravcukova B; Muzik J; Kuglik P; Vranova V; Falkova I; Hrabalkova R; Smardova J
    Int J Oncol; 2011 Dec; 39(6):1413-20. PubMed ID: 21874232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The lymphocyte to monocyte ratio improves the IPI-risk definition of diffuse large B-cell lymphoma when rituximab is added to chemotherapy.
    Rambaldi A; Boschini C; Gritti G; Delaini F; Oldani E; Rossi A; Barbui AM; Caracciolo D; Ladetto M; Gueli A; De Crescenzo A; Passera R; Devizzi L; Patti C; Gianni AM; Tarella C
    Am J Hematol; 2013 Dec; 88(12):1062-7. PubMed ID: 23940056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of age, Charlson comorbidity index, and performance status on treatment of elderly patients with diffuse large B cell lymphoma.
    Lin TL; Kuo MC; Shih LY; Dunn P; Wang PN; Wu JH; Tang TC; Chang H; Hung YS
    Ann Hematol; 2012 Sep; 91(9):1383-91. PubMed ID: 22526364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse prognosis of bulky disease in good-risk DLBCL.
    Ribera JM
    Lancet Oncol; 2008 May; 9(5):406-7. PubMed ID: 18452849
    [No Abstract]   [Full Text] [Related]  

  • 11. Matched-pair analysis comparing the outcomes of T cell/histiocyte-rich large B cell lymphoma and diffuse large B cell lymphoma in patients treated with rituximab-CHOP.
    Kim YS; Ji JH; Ko YH; Kim SJ; Kim WS
    Acta Haematol; 2014; 131(3):156-61. PubMed ID: 24192382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. R-CHOP therapy alone in limited stage diffuse large B-cell lymphoma.
    Tomita N; Takasaki H; Miyashita K; Fujisawa S; Ogusa E; Matsuura S; Kishimoto K; Numata A; Fujita A; Ohshima R; Kuwabara H; Hagihara M; Hashimoto C; Takemura S; Koharazawa H; Yamazaki E; Fujimaki K; Taguchi J; Sakai R; Ishigatsubo Y
    Br J Haematol; 2013 May; 161(3):383-8. PubMed ID: 23432318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study.
    Pfreundschuh M; Ho AD; Cavallin-Stahl E; Wolf M; Pettengell R; Vasova I; Belch A; Walewski J; Zinzani PL; Mingrone W; Kvaloy S; Shpilberg O; Jaeger U; Hansen M; Corrado C; Scheliga A; Loeffler M; Kuhnt E;
    Lancet Oncol; 2008 May; 9(5):435-44. PubMed ID: 18400558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial.
    Delarue R; Tilly H; Mounier N; Petrella T; Salles G; Thieblemont C; Bologna S; Ghesquières H; Hacini M; Fruchart C; Ysebaert L; Fermé C; Casasnovas O; Van Hoof A; Thyss A; Delmer A; Fitoussi O; Molina TJ; Haioun C; Bosly A
    Lancet Oncol; 2013 May; 14(6):525-33. PubMed ID: 23578722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High Ki-67 expression in diffuse large B-cell lymphoma patients with non-germinal center subtype indicates limited survival benefit from R-CHOP therapy.
    Li ZM; Huang JJ; Xia Y; Zhu YJ; Zhao W; Wei WX; Jiang WQ; Lin TY; Huang HQ; Guan ZZ
    Eur J Haematol; 2012 Jun; 88(6):510-7. PubMed ID: 22413767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma TNF-alpha and IL-10 level-based prognostic model predicts outcome of patients with diffuse large B-Cell lymphoma in different risk groups defined by the International Prognostic Index.
    Lech-Maranda E; Bienvenu J; Broussais-Guillaumot F; Warzocha K; Michallet AS; Robak T; Coiffier B; Salles G
    Arch Immunol Ther Exp (Warsz); 2010 Apr; 58(2):131-41. PubMed ID: 20191326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group.
    Li X; Liu Z; Cao J; Hong X; Wang J; Chen F; Wang C; Zou S; Li J; Shen Z
    Ann Hematol; 2012 Jun; 91(6):837-45. PubMed ID: 22160255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comorbidity is an independent prognostic factor in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP: a population-based cohort study.
    Wieringa A; Boslooper K; Hoogendoorn M; Joosten P; Beerden T; Storm H; Kibbelaar RE; Veldhuis GJ; van Kamp H; van Rees B; Kluin-Nelemans HC; Veeger NJ; van Roon EN
    Br J Haematol; 2014 May; 165(4):489-96. PubMed ID: 24754632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathologic features of the nine patients with primary diffuse large B cell lymphoma of the breast.
    Seker M; Bilici A; Ustaalioglu BO; Yilmaz B; Ozturk B; Ünal A; Dane F; Ozdemir NY; Elkiran ET; Kalender ME; Gumus M; Benekli M
    Arch Gynecol Obstet; 2011 Aug; 284(2):405-9. PubMed ID: 20872226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP.
    Sehn LH; Scott DW; Chhanabhai M; Berry B; Ruskova A; Berkahn L; Connors JM; Gascoyne RD
    J Clin Oncol; 2011 Apr; 29(11):1452-7. PubMed ID: 21383296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.